Premium
Myriad Genetics Inc (MYGN)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | Mr. Paul M. BisaroIndependent Director | 7,50k | 27,64k | Achat | 3,69 | 47,65k | 18,68% |
| 2026-05-01 | Mr. Brian DonnellyChief Commercial Officer | -55,98k | 268,68k | Sale to Issuer | 4,80 | 54,04k | -50,88% |
| 2026-04-14 | Mr. Mark S. VerrattiCOO | -1,07k | 5,25k | Sale to Issuer | 4,91 | 629,65k | -0,17% |
| 2026-04-14 | Dr. Dale MuzzeyChief Scientific Officer | -946,00 | 4,64k | Sale to Issuer | 4,91 | 326,31k | -0,29% |
| 2026-03-22 | Mr. Benjamin R. WheelerCFO & Principal Accounting Officer | -549,00 | 2,51k | Sale to Issuer | 4,58 | 298,51k | -0,18% |
| 2026-03-22 | Dr. Dale MuzzeyChief Scientific Officer | -2,02k | 9,25k | Sale to Issuer | 4,58 | 327,26k | -0,61% |
| 2026-03-22 | Mr. Mark S. VerrattiCOO | -2,06k | 9,41k | Sale to Issuer | 4,58 | 630,72k | -0,32% |
| 2026-03-13 | Dr. Kevin Richard HaasInitié | -22,31k | 103,96k | Sale to Issuer | 4,66 | 180,02k | -11,03% |
| 2026-03-13 | Ms. Shereen SolaimanCPO | -14,68k | 68,42k | Sale to Issuer | 4,66 | 34,86k | -29,63% |
| 2026-03-13 | Mr. Benjamin R. WheelerCFO & Principal Accounting Officer | -4,75k | 22,14k | Sale to Issuer | 4,66 | 299,06k | -1,56% |
| 2026-03-13 | Mr. Mark S. VerrattiCOO | -29,29k | 136,49k | Sale to Issuer | 4,66 | 632,77k | -4,42% |
| 2026-03-13 | Ms. Jennifer L. FoxChief Legal Officer | -6,00k | 27,94k | Sale to Issuer | 4,66 | 26,06k | -18,70% |
| 2026-03-13 | Dr. Dale MuzzeyChief Scientific Officer | -37,80k | 176,14k | Sale to Issuer | 4,66 | 329,28k | -10,30% |
| 2026-03-13 | Mr. Samraat S. RahaPresident, CEO & Director | -47,12k | 219,58k | Sale to Issuer | 4,66 | 161,98k | -22,54% |
| 2026-03-09 | Mr. Samraat S. RahaPresident, CEO & Director | 40,00k | 199,84k | Achat | 5,00 | 115,43k | 53,03% |
| 2026-03-01 | Ms. Shereen SolaimanCPO | -1,68k | 7,72k | Sale to Issuer | 4,61 | 14,82k | -10,16% |
| 2026-02-25 | Ms. S. Louise PhanstielIndependent Chair of the Board | 104,51k | 494,72k | Achat | 4,66 - 4,80 | 265,27k | 65,01% |
| 2026-01-01 | Dr. Dale MuzzeyChief Scientific Officer | -418,00 | 2,57k | Sale to Issuer | 6,15 | 170,18k | -0,25% |
| 2025-12-25 | Mr. Benjamin R. WheelerCFO & Principal Accounting Officer | -21,00 | 137,55 | Sale to Issuer | 6,55 | 92,63k | -0,02% |
| 2025-12-11 | Mr. Samraat S. RahaPresident, CEO & Director | -29,63k | 216,33k | Sale to Issuer | 7,30 | 75,43k | -28,20% |
| 2025-09-21 | Mr. Mark S. VerrattiCOO | -1,09k | 8,43k | Sale to Issuer | 7,77 | 381,83k | -0,28% |
| 2025-09-21 | Ms. Natalie MunkInitié | -962,00 | 7,47k | Sale to Issuer | 7,77 | 45,17k | -2,09% |
| 2025-09-21 | Mr. Benjamin R. WheelerCFO & Principal Accounting Officer | -2,56k | 19,88k | Sale to Issuer | 7,77 | 92,65k | -2,69% |
| 2025-09-21 | Ms. Margaret AnconaInitié | -958,00 | 7,44k | Sale to Issuer | 7,77 | 38,91k | -2,40% |
| 2025-09-03 | Ms. Jennifer L. FoxChief Legal Officer | -4,44k | 30,16k | Sale to Issuer | 6,80 | 11,01k | -28,72% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
